Concr

📍 Esher, United Kingdom🗓 Founded 2018👥 16 employees💰 Last funded Jun 2023
Biotechnology Research🌐 concr.co
Website LinkedIn
Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient-specific biomarkers of response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate composite tumour models. Using Concr’s cloud native platform – FarrSight® – researchers can make advanced predictions about biomarkers by leveraging Concr’s unique technology, and perform standard bioinformatics analyses directly. Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Cambridge Angels, Deep Science Ventures and SyndicateRoom.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Concr?
Concr has 1 investors on record on gritt.io, 1 mid-stage.
When did Concr last raise funding?
The most recent investment in Concr recorded on gritt.io was in June 2023.
When was Concr founded?
Concr was founded in 2018.
What industry is Concr in?
Concr operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Concr based?
Concr is headquartered in Esher, United Kingdom.